Conditional registration of an orphan medicine in the EAEU gives a 1-year certificate. Exceptional circumstances give 5 years
A registration certificate for an orphan medicine (a medicine intended to treat rare diseases) can be obtained on the basis of an incomplete dossier. This is provided for by the Rules for Registration and Regulatory Review of Medicines for Medical Use that apply in the Eurasian Economic Union (EAEU) and were approved by Decision of the Council of the Eurasian Economic Commission (EEC) No. 78 of 3 November 2016 (hereinafter Rules No. 78).
Rules No. 78 provide for two such procedures: registration under exceptional circumstances and conditional registration. The first applies where a complete dossier cannot be compiled for objective reasons. The second applies where the applicant will provide the missing data after registration. The choice of procedure determines the applicant’s obligations after registration and how the authorized body checks each year that they are met.
What an orphan medicine is and how to confirm its status in Russia
Under Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (hereinafter 61-FZ), orphan medicines are medicines intended exclusively for the diagnosis, etiopathogenetic treatment or pathogenetic treatment of rare diseases. Under Federal Law No. 323-FZ of 21 November 2011 «On the Fundamentals of Health Protection of Citizens in the Russian Federation» (hereinafter 323-FZ), rare diseases are those with a prevalence of no more than 10 cases per 100,000 people. The Russian Ministry of Health (hereinafter the Ministry) compiles the list of rare diseases and publishes it on its website.
A medicine is recognized as an orphan medicine under the legislation of each EAEU member state. If a medicine is recognized as an orphan medicine in the territories of all or several member states, it is registered through the mutual recognition procedure or the decentralized procedure, taking account of the specific requirements for orphan medicines. Under both procedures, one state (the reference state) assesses the medicine and prepares an assessment report, and the other states (the states of recognition) evaluate that report.
Registration under the requirements for orphan medicines also applies where a medicine is intended to treat an orphan disease from the list of an individual member state and is registered only for the market of that state (the national registration procedure). In a member state where the medicine is not recognized as an orphan medicine, it is registered under the general requirements.
In Russia, orphan status is determined by an expert assessment under 61-FZ. It can be carried out for both registered and unregistered medicines, that is, before the registration dossier is submitted. Up to 30 working days are allowed for the assessment, the preparation of the expert panel’s opinion and its transmission, counted from the date the assessment assignment is sent to the expert institution (the organization to which the Ministry sends the assignment). If the materials are insufficient, the expert institution requests them from the applicant. The applicant has up to 60 working days to respond, and the assessment period is suspended for that time. The Ministry then evaluates the opinion and, within 5 working days, sends the applicant a notification of the results with a copy of the expert opinion.
If the disease is not classified as rare under 323-FZ, the set of documents for the assessment includes a justification of orphan status with detailed information on diagnosis, prevention or treatment. It also includes the details of the document confirming payment of the state fee. Under the Tax Code of the Russian Federation, the fee for assessing documents submitted to determine whether a medicine can be considered an orphan medicine is RUB 420,000.
Registration under exceptional circumstances
Registration under exceptional circumstances means that a registration certificate is issued without complete data on efficacy and safety under normal conditions of use. The applicant must show, on objective and verifiable grounds, that it is impossible to provide such data.
The reason must fall within one of the following grounds under Rules No. 78:
The indications for use are encountered so rarely that the applicant cannot reasonably be expected to provide thorough evidence of efficacy and safety.
In the current state of scientific knowledge, complete information on efficacy or safety cannot be provided.
Obtaining such information would be contrary to generally accepted principles of medical ethics.
If the applicant considers that the grounds for registration under exceptional circumstances apply, it states this in the registration application. The justification of why complete data cannot be provided is submitted in subsection 1.8.2 of Module 1 (the administrative part of the registration dossier). The justification includes a statement that the applicant is unable to provide complete non-clinical or clinical data on safety and efficacy, a list of the available non-clinical and clinical data, the arguments for the grounds relied on, and proposals for special obligations. For orphan medicines, the applicant explains in the non-clinical and clinical summaries why complete information is unavailable and provides a justification of the benefit-risk balance of the medicine.
If the applicant relies on the rarity of the indication, the following are needed: epidemiological data on the low prevalence of the disease worldwide, an estimate of the size of the patient population available for studies, and a description of previous studies in comparable patient populations. The applicant also assesses whether the required studies, including joint multicenter studies, can be conducted. The justification states whether the medicine has orphan status in the member states. That status is not enough to justify the inability to provide complete data.
Under Rules No. 78, a registration certificate issued in this way comes with special obligations.
They include:
completing, within a set period, a program of safety or efficacy studies whose results will allow the benefit-risk balance to be reassessed;
the dispensing category «prescription medicines» and, in certain cases, use only under strict medical supervision (for radiopharmaceuticals, under the supervision of a person holding the relevant permit);
a statement in the summary of product characteristics (SmPC), the package leaflet, the registration certificate and any medical information that the data on the medicine are insufficient to confirm certain aspects of its safety or efficacy.
Rules No. 78 also contain a detailed description of the procedure for registration under exceptional circumstances. There the same obligations are set out in softer terms: they «may include» the requirements named above, and four types of special obligations are listed. These are a program of studies, conditions for prescribing or administering the medicine, obligations to notify the authorities, and obligations to amend the information on the medicine. The list of imposed obligations is given in an annex to the registration certificate and recorded in the unified register, and the conditions of use are entered in the SmPC and the package leaflet.
Once a year, the authorized body of the reference state reassesses the conditions of registration, that is, the applicant’s special obligations, and prepares a new assessment report on the medicine. The registration certificate is issued for 5 years, and re-registration is carried out under the rules on re-registration. The next registration certificate may be valid indefinitely unless the authorized body, on objective grounds related to pharmacovigilance results (monitoring of the medicine’s safety after it reaches the market), orders another re-registration after 5 years.
Conditional registration and what to submit for it
Conditional registration means that a registration certificate is issued before all data are available. It is used where the benefit of earlier availability of the medicine outweighs the risk associated with the absence of some data, and the applicant is likely to provide the missing data after registration.
If the dossier lacks clinical data, conditional registration is possible. In emergencies and in the case of a threat to public health, non-clinical data or the Module 3 data on the quality of the medicine may also be incomplete.
Conditional registration is available for medicines in one of the following categories:
intended for the treatment, prevention or diagnosis of serious (severe), debilitating or life-threatening diseases;
intended for use in the case of a threat to public health recognized by the World Health Organization or by the authorized body of a member state;
having orphan status or recognized as orphan medicines in the member states.
Conditional registration is requested when the registration application is submitted under the decentralized procedure or the mutual recognition procedure, that is, for registration in several member states. Before submitting the application, the applicant may notify the authorized body of the reference state in writing of its intention to request conditional registration. The request itself is included in the application and in subsection 1.2.1 of Module 1.
The request sets out the data supporting the possibility of conditional registration, proposals for completing ongoing or new studies and, where needed, proposals for pharmacovigilance. For an orphan medicine, a copy of the decision of the authorized body of the reference state granting orphan status, or other documentary evidence of the status, is attached to the request. The authorized body of the reference state may also itself propose conditional registration in its assessment report on the application, after consulting the applicant.
In the summary submitted in subsection 1.8.2.9 of Module 1, the applicant substantiates the following:
The benefit-risk balance of the medicine is positive.
After registration, the applicant will be able to provide complete clinical data and, where necessary, non-clinical and quality data.
Registration will meet unmet medical needs (they exist where the EAEU has no approved method of diagnosis, prevention or treatment for the condition, or where the new medicine offers a substantial advantage over an approved method).
The public health benefit of admitting the medicine to the market outweighs the risk associated with the absence of some data.
The authorized body of the reference state assesses whether conditional registration is possible and appropriate. If the planned scope of clinical studies does not allow them to be completed within the stated period, this may lead to refusal of conditional registration.
Obligations and validity of the registration certificate under conditional registration
The authorized body of the member state sets the special conditions of registration and the final deadline for meeting them, and also assesses each year how they are being met. For example, the registration holder (the person in whose name the registration certificate is issued) is required to complete an ongoing study or conduct a new one to confirm a positive benefit-risk balance, and the authorized body checks progress once a year. The list of obligations is stated in the registration certificate placed in the unified register. The SmPC and the package leaflet must contain a statement that the medicine is registered on special conditions.
A registration certificate issued under conditional registration is valid for 1 year. The application for confirmation is submitted no later than 6 months before the registration certificate expires. A decision is taken within 60 working days of receipt of the application. If the application is submitted on time, the registration certificate remains valid until the decision is taken. For example, if the registration certificate expires on 1 March 2028, the application is submitted no later than 1 September 2027. Once the special conditions have been met, the authorized body may, on the application of the registration holder and after a favorable opinion of the expert organization, issue a registration certificate for 5 years, with re-registration under the rules on re-registration.
The deadlines for the periodic safety update report (PSUR) have to be changed to take annual confirmation into account, and the new deadlines are recorded in the annexes to the registration certificate. If the registration holder fails to meet additional requirements or obligations, the authorized body of the reference state acts under the rules on suspension and revocation (cancellation) of the registration certificate.
How the two procedures differ and where accelerated assessment fits in
Where the applicant has substantiated conditional registration, registration under exceptional circumstances is not carried out. Conditional registration is carried out where complete clinical data are lacking, provided the applicant can submit them in the shortest possible time.
Table 1. Registration under exceptional circumstances and conditional registration under Rules No. 78
| Parameter | Registration under exceptional circumstances | Conditional registration |
|---|---|---|
| Legal basis | Rules No. 78: the main provision on registration under exceptional circumstances and a separate document attached to it | Rules No. 78: the provisions on conditional registration and a separate document attached to them |
| Why the dossier is incomplete | A complete dossier cannot, in principle, be compiled for objective reasons (one of the three grounds in Rules No. 78) | The applicant is likely to submit the missing data after registration |
| Which data are incomplete | Non-clinical or clinical | Clinical; in emergencies also non-clinical data and Module 3 data |
| Benefit and risk of the medicine | For orphan medicines, the applicant provides a justification of the benefit-risk balance | The balance is positive, and the benefit of earlier availability outweighs the risk of missing data |
| Review of the conditions of registration and validity of the certificate | Special obligations are reassessed every year; the registration certificate is issued for 5 years | 1 year with annual confirmation; after the special conditions are met, a registration certificate for 5 years can be obtained |
Accelerated assessment shortens the review period. It applies to orphan medicines, to medicines intended exclusively for minors, and to medicines of particular importance for public health, which are determined by the Expert Committee on Medicines at the request of the authorized body of a member state. Registration and assessment in the reference state take no more than 100 working days from the date the application is submitted to the day the registration certificate is issued. The request for accelerated assessment is included in the application for conditional registration, together with a list of post-registration measures.
Registration of an orphan medicine under Resolution No. 593
The special provisions governing the circulation of medicines in the event of a shortage (a lack of the medicine on the market) or a risk of shortage (hereinafter the Special Provisions) were approved by Resolution of the Government of the Russian Federation No. 593 of 5 April 2022 (hereinafter Resolution No. 593). Resolution No. 593 is in force until 31 December 2027. Under the Special Provisions, the Ministry registers a medicine within 60 working days of receiving the documents.
This procedure applies to a medicine for which an interdepartmental commission, whose composition is approved by the Ministry, has established a shortage or a risk of shortage. The commission’s opinion is part of the application, and its absence is a ground for refusal. Orphan status alone is therefore not enough to use this procedure.
The version of the Special Provisions of 10 August 2026 has applied since 20 August 2026. The information on the basis of which the commission determines a shortage now includes the absence of manufacturing in Russia at all stages, including synthesis of the active substance molecule. The application includes information on the manufacturing stages in Russia, separately for biological medicines and for all others (finished dosage form, packaging and release quality control). This information is provided by a Russian legal entity if the medicine has not previously been manufactured in Russia at the relevant stages.
For orphan medicines, the dossier includes the clinical study reports available at the time of application, including reports of studies conducted outside Russia in accordance with Good Clinical Practice (bioavailability, pharmacokinetics, pharmacodynamics, efficacy and safety). The Ministry may set mandatory post-registration clinical studies as a condition of registration, and their results will serve as the basis for assessing the benefit-risk balance when registration is confirmed.
A registration certificate under this procedure is issued through 31 December 2027. The application for confirmation of registration has to be submitted no later than 1 December 2027. The Ministry reviews such an application for up to 20 working days. Among other documents, the results of efficacy and safety monitoring in the form set by the Ministry are attached to the application. Confirmation can be refused only if the Ministry has decided that the risk of harm to health outweighs the efficacy of the medicine.
Real-world data
The rules for using real-world data (information collected during routine use of a medicine in medical practice) are set out in the Guideline on General Aspects of the Use of Real-World Data, annexed to Recommendation of the EEC Board No. 15 of 10 June 2025 (hereinafter the Guideline). Such data can be submitted in response to additional requirements during registration. Member states are invited to apply the Guideline from 10 July 2025, that is, after 30 calendar days from the publication of the Recommendation on the official EAEU website (10 June 2025). The authorized body assesses whether the submitted data comply with the Guideline.
It is proposed that the protocol and the statistical analysis plan be drawn up before the analysis begins and that an observational study start after approval by an ethics committee (in certain cases, a justified absence of approval is allowed). Studies for marketing purposes are not allowed.
What to do
Confirm orphan status before submitting the dossier. Submit an application for the assessment under 61-FZ and pay the state fee of RUB 420,000. Allow up to 30 working days for the assessment from the date the assignment is sent to the expert institution. The Ministry has up to a further 5 working days to evaluate the opinion. If the expert institution requests materials, add up to 60 working days for your response. For conditional registration you will need a copy of the decision granting the status or other documentary evidence of the status.
Choose the procedure according to the data you will be able to collect. If one of the three grounds for registration under exceptional circumstances applies, prepare the justification for subsection 1.8.2 of Module 1 with epidemiological data and state the procedure in the application. If the missing data will be provided after registration, prepare the request for subsection 1.2.1 of Module 1 and the summary for subsection 1.8.2.9 of Module 1. Conditional registration is requested when the application is submitted under the decentralized procedure or the mutual recognition procedure. The request for accelerated assessment is included in the application for conditional registration. With accelerated assessment, registration and assessment in the reference state take no more than 100 working days.
Request scientific advice before submission. The authorized body of the reference state is required to provide a mechanism for scientific advice on the possibility of conditional registration. Discuss the plan for post-registration studies and the scope of the incomplete data. At the same time, you can notify the authorized body in writing of your intention to request conditional registration.
Prepare a plan of post-registration obligations and a calendar of deadlines. Include the study program with its completion deadline, the schedule of periodic safety update reports and, if you use real-world data, the study protocol drawn up before the data are analyzed. If the planned scope of clinical studies does not allow them to be completed within the stated period, conditional registration may be refused. Mark in the calendar the date for submitting the application for confirmation, which is no later than 6 months before the registration certificate for conditional registration expires, and the annual reassessment deadline for registration under exceptional circumstances.
Check whether the procedure under Resolution No. 593 applies. It requires the conclusion of the interdepartmental commission on a shortage or a risk of shortage. Registration takes 60 working days, and the registration certificate is valid through 31 December 2027. The application for confirmation of registration has to be submitted no later than 1 December 2027.
For conditional registration of an orphan medicine, the dossier includes the document granting the status, a justification covering the four points of the summary, and a plan of studies after registration. For registration under exceptional circumstances, a justification based on one of the three grounds and proposals for special obligations are required.
Regulatory framework:
1. Decision of the EEC Council No. 78 of 3 November 2016 «On Approval of the Rules for Registration and Regulatory Review of Medicines for Medical Use» (version of 26 November 2025)
2. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (version of 4 August 2026)
3. Federal Law No. 323-FZ of 21 November 2011 «On the Fundamentals of Health Protection of Citizens in the Russian Federation» (version of 4 August 2026)
4. Tax Code of the Russian Federation, Part Two (version of 4 August 2026)
5. Resolution of the Government of the Russian Federation No. 593 of 5 April 2022 «On Special Provisions Governing the Circulation of Medicines for Medical Use in the Event of a Shortage or a Risk of Shortage of Medicinal Products in Connection with the Imposition of Restrictive Economic Measures against the Russian Federation» (version of 10 August 2026)
6. Recommendation of the EEC Board No. 15 of 10 June 2025 «On the Guideline on General Aspects of the Use of Real-World Data in the Circulation of a Medicinal Product»